ACRS Q4 2023 Earnings — Aclaris Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ACRSAclaris Therapeutics, Inc.

$435M

Q4 2023 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$18M+126.6% YoY

Gross Profit

$11M63.4% margin

Operating Income

-$4M-23.0% margin

Net Income

-$1M-8.5% margin

EPS (Diluted)

$-0.02

QoQ Revenue Growth

+89.3%

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$7M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$197M

Total Liabilities

$40M

Stockholders' Equity

$157M

Cash & Equivalents

$40M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$18M	$8M	+126.6%
Gross Profit	$11M	$6M	+78.6%
Operating Income	-$4M	-$29M	+86.1%
Net Income	-$1M	-$28M	+94.6%

Revenue Segments

License and Service

$26M95%

Contract research

$1M5%